Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimized Anti-HCV Treatment in HIV Co-infected Patients (ETOC)
NCT00901524Phase 2Completed
- Sponsor
- ANRS
- Start
- Jun 2009
- Primary completion
- Jun 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2a, ribavirin in hepatitis C (HCV), sponsored by ANRS. Started Jun 2009; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00901524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00901524.